文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

非浸润性乳头状尿路上皮肿瘤:2004 年 WHO/国际泌尿病理学会分类系统。

Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system.

机构信息

Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA.

出版信息

Pathol Int. 2010 Jan;60(1):1-8. doi: 10.1111/j.1440-1827.2009.02477.x.


DOI:10.1111/j.1440-1827.2009.02477.x
PMID:20055945
Abstract

The classification and grading of papillary urothelial neoplasms has been a long-standing subject of controversy. Previously, numerous diverse grading schemes for bladder tumor, including the 1973 World Health Organization (WHO) classification, existed whereby one of the major limitations was poor inter-observer reproducibility among pathologists. The WHO/International Society of Urological Pathology (ISUP) consensus classification system of urothelial neoplasms of the urinary bladder was developed in 1998 and was revised most recently in 2003 (published in 2004). Importantly, the current classification system provides detailed histological criteria for papillary urothelial lesions and allows for designation of a lesion (papillary urothelial neoplasm of low malignant potential) with a negligible risk of progression. Thus, the latest system is designed to be a universally acceptable one for bladder tumors that not only could be effectively used by pathologists, urologists, and oncologists, but also stratifies the tumors into prognostically significant categories. This article outlines the 2004 WHO/ISUP classification system regarding the specific histological criteria for non-invasive papillary urothelial neoplasms and the clinical significance of each category.

摘要

乳头状尿路上皮肿瘤的分类和分级一直是一个备受争议的话题。此前,存在许多不同的膀胱肿瘤分级方案,包括 1973 年世界卫生组织(WHO)的分类,其中一个主要的局限性是病理学家之间的观察者间重复性差。1998 年制定了世界卫生组织/国际泌尿病理学会(ISUP)共识的膀胱尿路上皮肿瘤分类系统,并于 2003 年进行了最近一次修订(2004 年出版)。重要的是,目前的分类系统为乳头状尿路上皮病变提供了详细的组织学标准,并允许指定具有低进展风险的病变(低度恶性潜能的乳头状尿路上皮肿瘤)。因此,最新的系统旨在成为一种普遍接受的膀胱肿瘤分类系统,不仅可以被病理学家、泌尿科医生和肿瘤学家有效使用,而且还可以将肿瘤分为具有预后意义的类别。本文概述了 2004 年 WHO/ISUP 分类系统关于非浸润性乳头状尿路上皮肿瘤的具体组织学标准和每个类别的临床意义。

相似文献

[1]
Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system.

Pathol Int. 2010-1

[2]
Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases.

Am J Clin Pathol. 2010-5

[3]
Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up.

Am J Clin Pathol. 2004-5

[4]
Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.

Mod Pathol. 2001-4

[5]
Cytologic diagnosis of low-grade papillary urothelial neoplasms (low malignant potential and low-grade carcinoma) in the context of the 1998 WHO/ISUP classification.

Diagn Cytopathol. 2003-4

[6]
The effects of the current World Health Organization/International Society of Urologic Pathologists bladder neoplasm classification system on urine cytology results.

Cancer. 2002-6-25

[7]
Urothelial neoplasia of the urinary bladder--comparison of interobserver variability for WHO Classification 1972 with WHO/ISUP Consensus Classification 1998.

J Ayub Med Coll Abbottabad. 2006

[8]
Urothelial neoplasms in patients 20 years or younger: a clinicopathological analysis using the world health organization 2004 bladder consensus classification.

J Urol. 2005-11

[9]
Papillary urothelial neoplasm of low malignant potential: reliability of diagnosis and outcome.

BJU Int. 2004-6

[10]
Histologic grading of urothelial carcinoma: a reappraisal.

Hum Pathol. 2012-4-26

引用本文的文献

[1]
Protein disulfide isomerase-enriched extracellular vesicles from bladder cancer cells support tumor survival and malignant transformation in the bladder.

Oncogene. 2025-4-11

[2]
Prediction of recurrence risk in patients with non-muscle-invasive bladder cancer.

Asian J Urol. 2024-10

[3]
Bladder Neoplasia in Pediatric Patients-A Single-Center Experience Including a Case Series.

Children (Basel). 2023-9-25

[4]
The role of SOD2 and NOS2 genes in the molecular aspect of bladder cancer pathophysiology.

Sci Rep. 2023-9-2

[5]
Clinicopathologic features and prognostic significance of mixed (Low and high-grade) papillary urothelial carcinoma comparison with low and high-grade papillary urothelial carcinoma.

Virchows Arch. 2023-11

[6]
Variability, Expression, and Methylation of and Genes in Bladder Cancer Pathophysiology.

Int J Mol Sci. 2023-3-27

[7]
CXCR3 Expression Is Associated with Advanced Tumor Stage and Grade Influencing Survival after Surgery of Localised Renal Cell Carcinoma.

Cancers (Basel). 2023-2-4

[8]
Diagnostic accuracy of cystoscopic biopsy for tumour grade in outpatients with urothelial carcinoma of the bladder and the risk factors of upgrading.

Asian J Urol. 2023-1

[9]
The Paris System for reporting urinary cytology improves the negative predictive value of high-grade urothelial carcinoma.

BMC Urol. 2022-4-5

[10]
Urothelial Papilloma of the Urinary Bladder: A Case Report and Literature Review of a Rare Entity.

Cureus. 2022-2-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索